Accès gratuit
Med Sci (Paris)
Volume 25, Numéro 12, Décembre 2009
Anticorps monoclonaux en thérapeutique
Page(s) 1078 - 1084
Section I - De la conception à la production
Publié en ligne 15 décembre 2009
  1. Reichert JM. Monoclonal antibodies as innovative therapeutics. Curr Pharm Biotechnol 2008; 9 : 423–30.
  2. Scolnik P. mAbs: a business perspective. mAbs 2009; 1 : 1–6.
  3. Reichert J. Number of mAbs entering clinical study nearly tripled in last decade. Tufts Center for Study of Drug Development Impact Report 2008; 10 :1–4.
  4. Werner R. Economic aspects of commercial manufacture of biopharmaceuticals. J Biotechnol 2004; 113 : 171–82.
  5. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256 : 495–7.
  6. Roskos L, Davis C, Schwab G. The clinical pharmacology of therapeutic monoclonal antibodies. Drug Dev Res 2004; 61 : 108–20.
  7. Jones D, Kroos N, Anema R, et al. High-level expression of recombinant IgG in the human cell line per.c6. Biotechnol Prog 2003; 19 : 163–8.
  8. Yallop C, Raamsman M, Zuijderwijk M, et al. High level production of recombinant IgG in the human cell line PER.C6. In : Francesc Gòdia MF, ed. Animal cell technology meets genomics. Amsterdam : Springer Netherlands, 2005 : 533–6.
  9. Gurramkonda C, Adnan A, Gabel T, et al. Simple high-cell density fed-batch technique for high-level recombinant protein production with Pichia pastoris: application to intracellular production of Hepatitis B surface antigen. Microb Cell Fact 2009; 8 :13.
  10. Barnes LM, Dickson AJ. Mammalian cell factories for efficient and stable protein expression. Curr Opin Biotechnol 2006; 17 : 381–6.
  11. Kwaks TH, Otte AP. Employing epigenetics to augment the expression of therapeutic proteins in mammalian cells. Trends Biotechnol 2006; 24 : 137–42.
  12. Carter PJ. Potent antibody therapeutics by design. Nat Rev Immunol 2006; 6 : 343–57.
  13. Shields RL, Namenuk AK, Hong K, et al. High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J Biol Chem 2001; 276 : 6591–604.
  14. Vaccaro C, Zhou J, Ober RJ, et al. Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels. Nat Biotechnol 2005; 23 : 1283–8.
  15. Lim SF, Chuan KH, Liu S, et al. RNAi suppression of Bax and Bak enhances viability in fed-batch cultures of CHO cells. Metab Eng 2006; 8 : 509–22.
  16. Sung YH, Hwang SJ, Lee GM. Influence of down-regulation of caspase-3 by siRNAs on sodium-butyrate-induced apoptotic cell death of Chinese hamster ovary cells producing thrombopoietin. Metab Eng 2005; 7 : 457–66.
  17. Figueroa B Jr, Sauerwald TM, Mastrangelo AJ, et al. Comparison of Bcl-2 to a Bcl-2 deletion mutant for mammalian cells exposed to culture insults. Biotechnol Bioeng 2001; 73 : 211–22.
  18. Chiang GG, Sisk WP. Bcl-x(L) mediates increased production of humanized monoclonal antibodies in Chinese hamster ovary cells. Biotechnol Bioeng 2005; 91 : 779–92.
  19. Borth N, Mattanovich D, Kunert R, et al. Effect of increased expression of protein disulfide isomerase and heavy chain binding protein on antibody secretion in a recombinant CHO cell line. Biotechnol Prog 2005; 21 : 106–11.
  20. Davis R, Schooley K, Rasmussen B, et al. Effect of PDI overexpression on recombinant protein secretion in CHO cells. Biotechnol Prog 2000; 16 : 736–43.
  21. Bergemann K, Eckermann C, Garidel P, et al. Production and downstream processing. In : Dübel S, ed. Handbook of therapeutic antibodies. New York : Wiley, 2007 : 199–237.
  22. Foulon A, Trach F, Pralong A, et al. Using disposables in an antibody production process. BioProcess Int 2008; 6 : 12–7.
  23. The single-use technology guidebook. BioProcess Int 2008; 6 (suppl 3).
  24. Chartrain M, Chu L. Development and production of commercial therapeutic monoclonal antibodies in mammalian cell expression systems: an overview of the current upstream technologies. Curr Pharm Biotechnol 2008; 9 : 447–67.
  25. Scott C. Proactive debottlenecking. Planning ahead for the downstream bottleneck. BioProcess Int 2008; 6 : 32–42.
  26. Arunakumari A, Wang J, Figueroa B Jr. Advances in non-protein A purification processes for human monoclonal antibodies. Biopharm Int 2009 (suppl mars).
  27. Seaman C, Fries S, Beck A, et al. Cell cultivation process transfer and scale-up. In support of production of early clinical supplies of an anti IGF-1R antibody (part 1). BioProcess Int 2008; 6 : 26–36.
  28. Seaman C, Fries S, Beck A, et al. Cell cultivation process transfer and scale-up. In support of production of early clinical supplies of an anti IGF-1R antibody (part 2). BioProcess Int 2008; 6 : 34–42.
  29. Beck A, Wagner-Rousset E, Bussat MC, et al. Trends in glycosylation, glycoanalysis and glycoengineering of therapeutic antibodies and Fc-fusion proteins. Curr Pharm Biotechnol 2008; 9 : 482–501.
  30. Farid SS. Process economics of industrial monoclonal antibody manufacture. J Chromatogr B Analyt Technol Biomed Life Sci 2007; 848 : 8–18.
  31. Faye L, Champey Y. Plants, medicine and genetics, which applications for tomorrow ? Med Sci (Paris) 2008; 24 : 939–45.
  32. Cadoret JP, Bardor M, Lerouge P, et al. Microalgae as cell factories producing recombinant commercial proteins. Med Sci (Paris) 2008; 24 : 375–82.

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.